Search Results
Your search for can matches 13758 pages
Showing 5101 - 5150Community Oncology Alliance Elects Officers and New Board Members for 2020
The Community Oncology Alliance (COA) has announced the election of new and re-appointed members to the Board of Directors and Executive Committee. The Board and Committee are comprised of volunteer representatives from community oncology, who direct the management of COA by its Executive ...
Emerging Fertoprotective Therapeutic Options for Female Fertility Preservation
The trend toward delayed childbearing has meant that many women who plan to have children may be childless at the time they are diagnosed with cancer. The number of these women is likely to further increase concurrently with the increase in cancer survivors, making “the focus on fertility...
Fred Hutch Names Thomas J. Lynch, Jr, MD, as New President and Director
Fred Hutchinson Cancer Research Center recently announced that Thomas J. Lynch, Jr, MD, will become the center’s new President and Director. Dr. Lynch, a cancer expert in solid tumor research, precision medicine, and immuno-oncology, will join Fred Hutch on February 1. Dr. Lynch will become the...
Expert Point of View: Debra A. Patt, MD, MPH, MBA, FASCO, and C. Kent Osborne, MD, FASCO
Debra A. Patt, MD, MPH, MBA, FASCO, Clinical Professor at Dell Medical School at The University of Texas at Austin and Executive Vice President of Public Policy and Strategy Initiatives for Texas Oncology, told attendees in a symposium highlights talk, “We all identify and follow some patients who ...
Fam-trastuzumab Deruxtecan-nxki for Previously Treated Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, 2019, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was granted accelerated approval in the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2...
Atezolizumab With Chemotherapy for Metastatic Nonsquamous NSCLC Without EGFR/ALK Aberrations
On December 3, 2019, atezolizumab in combination with nab-paclitaxel and carboplatin was approved for first-line treatment of metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumore aberrations.1,2 The approval was based on findings in the open-label phase III...
Practicing Wellness to Reduce Burnout
Numerous wellness strategies are accessible to busy physicians and oncologists, which can be incorporated into their daily routine. Here we discuss such aspects as stress reduction, mindfulness, eating well, sleeping well, and spirituality for the wellness of oncologists. Those who regularly adhere ...
A Caregiver’s Tale of Struggle and Lingering Questions
The role of caregiver in the cancer scenario is complicated by various emotions and circumstances beyond the control of the caregiver and the person with cancer. Caregiver stress occurs when there isn’t the time to do all that’s asked or expected of one. Caregiver stress evolves into burnout when...
Forbes Magazine Names 2020 Class of 30 Under 30, Including Honorees in Science and Health Care
Forbes magazine released the ninth annual “30 Under 30” list Class of 2020 in December 2019, featuring the newest group of 600 young entrepreneurs, scientists, and innovative individuals who were recognized for their extraordinary accomplishments at early ages. A total of 30 honorees were selected...
Seven Haircuts
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
FDA Grants Breakthrough Therapy Designation to Tucatinib in Combination Therapy for HER2-Positive Breast Cancer
Seattle Genetics recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast...
Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases
For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...
Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
On December 16, 2019, enzalutamide (Xtandi) was approved for the treatment of patients with metastatic castration-sensitive prostate cancer.1,2 Supporting Efficacy Data The current approval was based on findings from the phase III double-blind ARCHES trial (ClinicalTrials.gov identifier...
Supportive Care in Oncology Symposium Emphasized Caring for the Whole Patient From Diagnosis to End of Life
The 2019 Supportive Care in Oncology Symposium: Advancing Palliative Research Across the Care Continuum, held this past October in San Francisco, marked the fifth anniversary of its inauguration and its last as a stand-alone ASCO thematic meeting. Since its launch in 2014 as the Palliative Care in...
New NCCN Pediatric Cancer Guidelines for B-Cell Lymphomas
The National Comprehensive Cancer Network® (NCCN®) has published new guidelines for treating children, adolescents, and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma. NCCN published the first pediatric NCCN Clinical...
2020 GI Cancers Symposium: Higher Concentration of Fusobacterium nucleatum Found in Colorectal Tumors in Patients Younger Than 45
A bacterium typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people younger than age 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly fourfold...
CancerCare to Provide Support for Patients With Cancer Impacted by the California Wildfires
As many California residents continue to deal with the aftermath of past wildfires and the advent of new ones, CancerCare is now offering a patient assistance program for both emotional and financial support to patients with cancer affected by the California fires. As a leading national nonprofit...
Ten Oncology Practices in Underserved Communities Receive Funding to Participate in Quality Improvement Programs
Ten oncology practices from rural and urban centers in the United States that primarily treat underserved populations have received grant funding to participate in ASCO’s Quality Oncology Practice Initiative (QOPI®) and Quality Training Program. The grants are supported by the Stavros Niarchos...
Motivating Yourself for Exercise Goals in the New Year
The day after Christmas, I walked into the exercise studio and spent the next hour jogging, rowing, and doing exactly what that morning’s coach instructed the 20 or so participants of the class to do next. The hour passed quickly, and I had little or no time to think about anything other than the...
FDA’s Pilot Project Patient Voice Website and Workshop With ASCO
Project Patient Voice (PPV) is a program that will gather and make available online, patient-reported outcomes from cancer clinical trials. Launched by the U.S. Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE), it is the first program of its kind to communicate...
Value-Based and Patient-Centered Cancer Care: Looking at Closing Gaps in Perspectives of Value
Value-based care in oncology—a concept that emphasizes quality over quantity—has evolved over the past 2 decades to become a guiding principle of both public and private payers. The concept was part of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008; informed elements of...
Two New Grants to Support Transformative Cancer Research
Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund. This unique grant program allows investigators to...
2020 GI Cancers Symposium: Young Adults With Colorectal Cancer Living in Areas of Low Income, Education Likely to Have Worse Survival Outcomes
A retrospective analysis of 26,768 young adults with colorectal cancer aged 40 and under found that those who live in areas with lower income (a median income of less than $38,000) and less education (under 79% high school graduation rate), as well as those who live in urban areas, had worse...
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care treatments in patients with unresectable hepatocellular carcinoma and BRAF V600E–mutant metastatic colorectal cancer. The results, from...
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers could potentially help detect disease at earlier stages. This research will be presented by Brian M. Wolpin, MD, MPH, and colleagues at the 2020 Gastrointestinal Cancers...
Expert Point of View: Hope S. Rugo, MD, FASCO, and Laura J. Esserman, MD, MBA, FASCO
Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials at the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, said the residual cancer burden index is being increasingly used in medical oncology. “The...
Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes
Residual cancer burden after neoadjuvant chemotherapy can accurately predict disease recurrence and survival across all breast cancer subtypes, according to the findings from a meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium by W. Fraser Symmans, MD, Professor and Director...
Expert Point of View: Michael Jain, MD, PhD
Michael Jain, MD, PhD, of the Moffitt Cancer Center, Tampa, Florida, commented on both studies with the combination of brentuximab vedotin/nivolumab. “For older patients, ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine] is not easy to tolerate, and it would be good to find an easier...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship....
Using T-Cell Fraction to Predict Melanoma Recurrence
In a paper published by Pruessmann et al in Nature Cancer, investigators presented a new, quantitative technique that leverages DNA sequencing to make more sophisticated and accurate predictions about which primary melanomas are likely to recur and spread. "As recently as 10 years ago, the outlook...
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Three Studies Examine Relationship Between B-Cell Enrichment and Response to Immunotherapy
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures, according to three studies all recently published in Nature. The studies showed that enrichment of B cells...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Conditioning Intensity for Allogeneic Transplantation in Patients With AML
In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD,...
Genomic Aberrations and Pancreatic Cancer Subtypes
Researchers have discovered detailed new genetic information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease, Chan-Seng-Yue et al reported in Nature Genetics. The study...
Are Women in Europe or Asia More Likely to Have Breast-Conserving Therapy Than Those in the United States?
Neoadjuvant systemic therapy can shrink tumors in patients with breast cancer and, in some cases, allow patients to receive breast-conserving therapy who would otherwise require mastectomy. However, in the United States, about 55% of patients who become eligible for breast-conserving therapy after...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL
Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...
Cancer Survivors Face Substantial Medical Financial Hardship
Although advances in cancer treatments have led to huge increases in the number of survivors in the United States—more than 16.9 million in 2019—many of those survivors, particularly those aged 18 to 64, face substantial medical financial hardship due to their diagnosis and treatment, necessitating ...
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
Researchers have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...
Higher 21-Gene Recurrence Score May Be Associated With Increased Risk of Locoregional Recurrence in Patients With Breast Cancer
A new study shows that a test physicians commonly use to guide chemotherapy for patients with breast cancer after surgery may also help them decide whether radiation therapy may be of benefit. Results published by Wendy A. Woodward, MD, PhD, and colleagues in JAMA Oncology suggest patients with an...
Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens including the monoclonal antibody daratumumab in combination ...
Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer May Have Different Rates of Mortality
New research indicates that there is a higher risk of early death among patients with oropharyngeal cancer not associated with human papillomavirus (HPV) vs those whose tumors are HPV-positive. The findings are published by Fullerton et al in Cancer. The incidence of oropharyngeal cancer is...
Molecular Characteristics of Leptomeningeal Melanoma Metastases
Patients with advanced melanoma who develop metastases in the leptomeninges usually have a poor prognosis—most patients only survive for 8 to 10 weeks after diagnosis. One reason for this poor prognosis is that very little is known about the molecular development of leptomeningeal melanoma...
Association Between Colorectal Cancer and Ulcerative Colitis
Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. Olén et al published these findings in The Lancet. Previous research has shown that patients with ulcerative ...
Transplantation Specialist Karen Ballen, MD, Treasures Long-Term Connections With Her Patients
Karen Ballen, MD, an international expert in stem cell transplantation, particularly for patients who have a difficult time finding a donor, was born and reared in the Bronx in a family that encouraged academic and professional pursuits. “My grandfather was an old-fashioned pediatrician who made...
Patient Access to High-Quality Oncologic Pathology Improves Care
Accurate and timely diagnoses are critical components for developing treatment plans for patients with cancer and also for informing prognosis and assessment of responses. Pathologists are an essential part of the oncology team because they have specialized knowledge that helps inform diagnostic...
Does Statin Use Increase Overall Survival in Patients With Colorectal Cancer?
About 40 million adults in the United States take a statin to lower their cholesterol and reduce the risk for heart disease—but they may also be getting an added anticancer benefit, a growing body of evidence suggests. According to research presented at the American Heart Association’s Scientific...
